Latest news with #CLABSI
Time of India
16 hours ago
- Health
- Time of India
AIIMS-led study finds infections contracted in hospital due to catheter use prevalent across India
New Delhi: Bloodstream infections acquired during a hospital stay due to the use of a catheter are prevalent across ICUs in India and are often caused by microbes having a high level of antibiotic resistance, according to a study led by the All India Institute of Medical Sciences, New Delhi. Antibiotic resistance -- in which antibiotic drugs are rendered ineffective because disease-causing microbes have become immune to them -- can extend one's hospital stay and treatment costs, adding stress to a public healthcare system. Estimates published in The Lancet Global Health journal show that on average, around nine bloodstream infection events occur every 1,000 days that a central line -- a catheter inserted in a patient's large vein instead of an intravenous line -- was in place in the intensive care units (ICUs) of Indian hospitals. 'Central line-associated bloodstream infections', or CLABSI, are preventable infections -- often acquired from a hospital environment -- and significantly contribute to illness and death in low- and middle-income countries, including India. The researchers said that tracking rates of bloodstream infections in ICUs can help countries develop preventive measures suited to a healthcare system. However, setting up a surveillance that systematically tracks infections due to catheter use or other hospital-acquired infections calls for a significant amount of resources and is a challenge in low- and middle-income countries, including India, they said. The team analysed data from 200 intensive care units received by the Indian Healthcare-Associated Infections (HAI) surveillance network from 54 hospitals across the country over a period of seven years. "During the surveillance period from May 1, 2017, to April 30, 2024, 8,629 laboratory-confirmed CLABSI events, 3,054,124 patient-days and 977,052 central line-days were recorded. The overall pooled CLABSI rate was 8.83 per 1,000 central line-days," the authors wrote. Highest rates of bloodstream infections linked to central line catheter use were seen to occur during 2020-21, coinciding with the COVID-19 pandemic, which the researchers said may be due to overwhelmed ICUs, staff shortage and compromised infection prevention measures. The study -- first large-scale observational one, providing a standardised surveillance report of CLABSI in India -- provides a valuable opportunity for a quality improvement-based approach for the reduction of CLABSI, the authors said.
The Hindu
19 hours ago
- Health
- The Hindu
AIIMS-led study finds infections contracted in hospital due to catheter use prevalent across India
Bloodstream infections acquired during a hospital stay due to the use of a catheter are prevalent across ICUs in India and are often caused by microbes having a high level of antibiotic resistance, according to a study led by the All India Institute of Medical Sciences, New Delhi. Bloodstream infections Antibiotic resistance -- in which antibiotic drugs are rendered ineffective because disease-causing microbes have become immune to them -- can extend one's hospital stay and treatment costs, adding stress to a public healthcare system. Estimates published in The Lancet Global Health journal show that on average, around nine bloodstream infection events occur every 1,000 days that a central line -- a catheter inserted in a patient's large vein instead of an intravenous line -- was in place in the intensive care units (ICUs) of Indian hospitals. 'Central line-associated bloodstream infections', or CLABSI, are preventable infections -- often acquired from a hospital environment -- and significantly contribute to illness and death in low- and middle-income countries, including India. The researchers said that tracking rates of bloodstream infections in ICUs can help countries develop preventive measures suited to a healthcare system. However, setting up a surveillance that systematically tracks infections due to catheter use or other hospital-acquired infections calls for a significant amount of resources and is a challenge in low- and middle-income countries, including India, they said. Study highlights The team analysed data from 200 intensive care units received by the Indian Healthcare-Associated Infections (HAI) surveillance network from 54 hospitals across the country over a period of seven years. "During the surveillance period from May 1, 2017, to April 30, 2024, 8,629 laboratory-confirmed CLABSI events, 3,054,124 patient-days and 977,052 central line-days were recorded. The overall pooled CLABSI rate was 8.83 per 1,000 central line-days," the authors wrote. Highest rates of bloodstream infections linked to central line catheter use were seen to occur during 2020-21, coinciding with the COVID-19 pandemic, which the researchers said may be due to overwhelmed ICUs, staff shortage and compromised infection prevention measures. The study -- first large-scale observational one, providing a standardised surveillance report of CLABSI in India -- provides a valuable opportunity for a quality improvement-based approach for the reduction of CLABSI, the authors said.
&w=3840&q=100)
Business Standard
a day ago
- Health
- Business Standard
Aiims study finds catheter infections in hospital widespread across India
Bloodstream infections acquired during a hospital stay due to the use of a catheter are prevalent across ICUs in India and are often caused by microbes having a high level of antibiotic resistance, according to a study led by the All India Institute of Medical Sciences, New Delhi. Antibiotic resistance -- in which antibiotic drugs are rendered ineffective because disease-causing microbes have become immune to them -- can extend one's hospital stay and treatment costs, adding stress to a public healthcare system. Estimates published in The Lancet Global Health journal show that on average, around nine bloodstream infection events occur every 1,000 days that a central line -- a catheter inserted in a patient's large vein instead of an intravenous line -- was in place in the intensive care units (ICUs) of Indian hospitals. 'Central line-associated bloodstream infections', or CLABSI, are preventable infections -- often acquired from a hospital environment -- and significantly contribute to illness and death in low- and middle-income countries, including India. The researchers said that tracking rates of bloodstream infections in ICUs can help countries develop preventive measures suited to a healthcare system. However, setting up a surveillance that systematically tracks infections due to catheter use or other hospital-acquired infections calls for a significant amount of resources and is a challenge in low- and middle-income countries, including India, they said. The team analysed data from 200 intensive care units received by the Indian Healthcare-Associated Infections (HAI) surveillance network from 54 hospitals across the country over a period of seven years. "During the surveillance period from May 1, 2017, to April 30, 2024, 8,629 laboratory-confirmed CLABSI events, 3,054,124 patient-days and 977,052 central line-days were recorded. The overall pooled CLABSI rate was 8.83 per 1,000 central line-days," the authors wrote. Highest rates of bloodstream infections linked to central line catheter use were seen to occur during 2020-21, coinciding with the Covid-19 pandemic, which the researchers said may be due to overwhelmed ICUs, staff shortage and compromised infection prevention measures. The study -- first large-scale observational one, providing a standardised surveillance report of CLABSI in India -- provides a valuable opportunity for a quality improvement-based approach for the reduction of CLABSI, the authors said.
Reuters
20-06-2025
- Health
- Reuters
AseptiScope Reports Major Success in Eliminating Life-Threatening Hospital Infections
SAN DIEGO, CA, June 20, 2025 (EZ Newswire) -- A promising new chapter in infection control has opened as AseptiScope, opens new tab® announces its recent peer-reviewed publication, opens new tab of clinical results using its DiskCover® System, a touch-free stethoscope hygiene solution, by the Journal of Infectiology and Epidemiology. The study documents how healthcare professionals at the Memphis VA Medical Center integrated the system into their infection prevention protocols, resulting in an unprecedented reduction of Central Line-Associated Bloodstream Infections (CLABSIs) to zero over a one-year period. Central Line-Associated Bloodstream Infections (CLABSIs) CLABSIs are among the most severe and preventable hospital-acquired infections, typically occurring when pathogens enter the bloodstream via a central venous catheter. These lines are commonly used in critical care to administer medication or collect diagnostic data. Despite rigorous hygiene protocols, including antiseptic bathing and aseptic line management, CLABSI rates persist, posing serious threats to already-vulnerable patients. Until now, stethoscope hygiene has never been included in CLABSI prevention bundles. 'The problem with central line infections is that critically ill patients are vulnerable, and these preventable occurrences can shift a routine procedure into a deadly, critical emergency,' stated Nicole Kupchik, clinical nurse specialist and leading authority on critical care nursing. 'This is not only a significant professional challenge, but I lost a dear friend going through cancer treatment to this preventable, deadly infection.' That changed when infection control specialists Naomi Ragsdale and Wendy Simpson at the Memphis VA took a bold step. Recognizing the stethoscope as a significant but often overlooked vector, frequently called the clinician's 'third hand,' they incorporated AseptiScope's DiskCover System into their CLABSI prevention strategy. The result: a complete elimination of CLABSIs over a 12-month span. AseptiScope's DiskCover System The DiskCover System works by automatically applying a sterile, single-use barrier to the diaphragm of a stethoscope, ensuring that each patient encounter begins with a clean device, something that traditional alcohol wipes fail to guarantee. In fact, numerous studies have shown that not only are alcohol wipes often used incorrectly or inconsistently, but some hospital pathogens are increasingly resistant to alcohol-based disinfectants altogether. Unlike manual cleaning, the DiskCover System is intuitive, immediate, and compatible with fast-paced clinical environments. Located near hand hygiene stations, the device activates with a wave of the stethoscope, applying a clean disk in a second, allowing for seamless patient care without compromising safety. Cindy Cadwell, a nurse practitioner, patient safety and quality expert, has been focused on the problem of stethoscope hygiene for years. 'Our clinical teams want to do all the right things, but today's world is fast moving, and even with the most diligent cleaning, more pathogens than ever are increasingly resistant to cleaning with alcohol and other disinfectants,' said Cadwell. 'So, a barrier system that breaks direct contact is exactly what we've been waiting for; high-quality infection control, that is both clinician and workflow friendly.' Kathleen Vollman, president of the World Federation of Critical Care Nurses, emphasized the implications: 'The stethoscope has been a problem without a solution for a long time, and it seems we finally have what we need here. Tools like this are elegant in their simplicity, but have a huge impact on healthcare. Ultimately, innovation like this saves patient lives, saves time for our clinical teams, and saves money for our hospitals.' Physicians, too, are taking note. Dr. Frank Peacock, a medical doctor, leading authority on stethoscope hygiene and infection control, and co-founder of AseptiScope, stated during an event for the CDC's Division of Healthcare Quality Promotion (DHQP) last year on the subject: 'Placing a disk cover barrier on stethoscopes using a touch-free dispenser means I barely break stride when applying them, and ensures clean patient exams for the first time in my career. The visible barrier doesn't just give me confidence, it also gives the patient comfort, which is fantastic." AseptiScope, a California-based medical device startup, was founded by a team of healthcare veterans. CEO Scott W. Mader, a longtime clinical innovation expert, said the company was born out of a recognition of the overlooked infection risks of stethoscopes. 'I've spent my career bringing health innovations to market, and when we say this enormous gap in patient safety, as the stethoscope is like the clinician touching patients with a dirty third hand,' said Mader. 'The touch-free application of the perfectly clean disk cover barrier blocks any pathogen exposure instantly'. While the DiskCover System is still relatively new to hospitals, its impact is expanding quickly. AseptiScope reports that major cancer centers, urgent care clinics, and primary care facilities are now deploying the device to protect patients, particularly those who are immunocompromised or medically fragile. 'Now our customers are confirming this is not just another product; it's a public health intervention,' Mader added. 'This low-cost, high-impact innovation could prevent life-threatening infections for millions of patients.' Looking forward, AseptiScope is developing additional touch-free devices based on the same principle of automated aseptic barriers. As the Memphis VA's success story gains national attention, hospitals across the U.S. are taking notice. In an age where healthcare systems are under enormous strain and antimicrobial resistance continues to rise, tools like the DiskCover System may offer a critical path forward. About AseptiScope AseptiScope is a healthcare technology company focused on infection prevention for both clinicians and patients. The company develops innovative aseptic solutions aimed at reducing the risk of contamination and infection within healthcare systems. Their flagship product, the DiskCover™ System, addresses the persistent issue of stethoscope contamination—a significant yet often overlooked vector for healthcare-associated infections (HAIs). The DiskCover System is an evidence-based, automated, and touch-free solution designed to create a highly visible and effective infection barrier during patient examinations, filling a critical gap in infection prevention technology. AseptiScope is led by a team of prominent medical professionals and experts in the field. For more information, visit opens new tab. Media Contact Anthony Pham apham@ ### SOURCE: AseptiScope Copyright 2025 EZ Newswire See release on EZ Newswire
Yahoo
12-06-2025
- Health
- Yahoo
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days. 70.5% reduction in the incidence of CLABSI in patients with Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs vs. plain (non-impregnated) catheters. Lower incidence of infection-causing pathogens with Chlorhexidine-impregnated CVCs, including gram-negative and gram-positive bacteria and fungi. Insertion training and the use of maximal barrier precautions were similar across both groups, eliminating technique variability as a confounding factor. Use of an unprotected CVC may be an independent risk factor for CLABSI when compared to patients with Chlorhexidine-impregnated CVCs. The study's CVC analysis demonstrated a statistically significant reduction in CLABSIs of 70.5% in patients receiving the impregnated antimicrobial catheters. These patients had longer average length of ICU stay and device utilization ratios, indicating frequent and extended use. Despite this, infection remained significantly lower, underscoring the potential benefit of the antimicrobial technology even in high-risk patients. Acknowledging potential variations in patients and characteristics across study hospitals and the lack of a metric (e.g., Standard Infection Ratio) to adjust for these factors in the countries in the study, the authors noted that the study data nonetheless provides 'significant evidence' regarding impregnated CVCs. According to Dr. Amy Bardin, Vice President of Clinical and Medical Affairs at Teleflex, this new multinational study suggests that even with proper training and adherence to best practices—including catheter insertion, care, and maximal barrier precautions—unprotected CVCs may be an independent risk factor for CLABSI compared to chlorhexidine-impregnated CVCs. This new research reinforces our performance claims for effectiveness of Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens. The study identified that patients with plain CVCs 'had a higher incidence of gram-negative bacteria, such as Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, gram-positive bacteria, such as Staphylococcus aureus, Enterococcus faecium, and fungi, such as Candida species.' The results from this study's Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVC subgroup analysis reinforce the effectiveness of Chlorhexidine on Arrow™ CVCs. The full results of this study can be accessed at About Teleflex IncorporatedAs a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. *The Rosenthal et al. study is referenced for only the pre-specified CVC subgroup analysis, which excludes PICCs (8 of the 6,672 catheters used in the study's overall analysis were PICCs). Arrowg+ard Blue Advance™ PICCs are not indicated for CLABSI reduction. Teleflex funded editorial support but was not involved in data analysis or manuscript content. Reference: Rosenthal VD, Yin R, Jin Z, et al. Multicenter, multinational, prospective cohort study of the impact of chlorhexidine impregnated versus plain central lines on central line-associated bloodstream infections. Am J Infect Control. Published online March 6, 2025. doi:10.1016/ Rx OnlyContraindications:The Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ Catheters are contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine and/or sulfa complete indications, contraindications, warnings, precautions, and adverse reactions, please reference each referenced product's full package insert. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue, Arrowg+ard Blue Advance, Arrowg+ard Blue Plus, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners. © 2025 Teleflex Incorporated. All rights reserved. MC-010846 Contact:Teleflex IncorporatedLawrence KeuschVice President, Investor Relations and Strategy in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
